Cochrane · systematic review · CD001989
Interventions for acute non‐arteritic central retinal artery occlusion
Lin, JC, Song, S, Ng, SM, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
Eyes and VisionAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
2
No studies
1
Included studies
NR
No studies 1 · 33.3%Ungraded 0 · 0%Very low 0 · 0%Low 2 · 66.7%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Tissue plasminogen activator (t‐PA) compared with standard treatment for acute non‐arteritic central retinal artery occlusion (CRAO)
Population: people with acute non‐arteritic CRAO
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Mean change in BCVA at 1 month (logMAR) Tissue plasminogen activator (t‐PA) vs standard treatment | no estimate extracted | 2 studies · 98 participants | Low Downgraded: imprecision |
Quality of life measures at 1 month Tissue plasminogen activator (t‐PA) vs standard treatment | no estimate extracted | NR | No studies |
Adverse events at 1 month Tissue plasminogen activator (t‐PA) vs standard treatment | no estimate extracted | 3 studies · 146 participants | Low Downgraded: imprecision |